Abilify

Main information

  • Trade name:
  • Abilify 30 mg Tablet
  • Dosage:
  • 30 mg
  • Pharmaceutical form:
  • Tablet
  • Units in package:
  • Blister pack, AL/Al - 5 tablets, 5 tablets
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Otsuka Pharmaceutical Co Ltd

Documents

Localization

  • Available in:
  • Abilify 30 mg Tablet
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • ABILIFY is indicated of the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 12921
  • Authorization date:
  • 18-08-2006
  • Last update:
  • 27-09-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

ABILIFY™

ABILIFY™

5mg, 10mg, 15mg, 20mg & 30mg tablet

Aripiprazole

Consumer Medicine Information

What is in this leaflet

This leaflet answers some common

questions about ABILIFY. It does

not contain all the available

information. Some of the information

contained in this leaflet may not

apply to you.

It does not take the place of talking to

your doctor or pharmacist.

All medicines have risks and

benefits. Your doctor has weighed

the risks of you taking ABILIFY

against the benefits it is expected to

have for you.

If you have any concerns about

taking this medicine, ask your

doctor or pharmacist.

Keep this leaflet with the medicine.

You may need to read it again.

What ABILIFY is used

for

ABILIFY is a trade name

(manufacturer's name) for the

medicine aripiprazole (Ari-pip-rah-

zol).

ABILIFY belongs to a group of

medicines called antipsychotic agents

which improve the symptoms of

certain types of mental illness.

ABILIFY is used to treat symptoms

of schizophrenia.

ABILIFY may be given to treat acute

episodes of sustained upward mood

swings (mania) in adult patients with

Bipolar 1 Disorder. During mania,

patients experience episodes of

overactivity, elation or irritability.

Schizophrenia is a mental illness

with disturbances in thinking,

feelings and behaviour.

Bipolar disorder is a condition with

symptoms such as feeling "high",

having excessive amounts of energy,

needing much less sleep than usual,

talking very quickly with racing

ideas and sometimes severe

irritability.

Your doctor may have prescribed

ABILIFY for another reason. Ask

your doctor if you have any questions

about why ABILIFY has been

prescribed for you.

There is no evidence that ABILIFY

is addictive.

This medicine is available only with

a doctor's prescription.

ABILIFY is not recommended for

use in children under the age of 18,

as safety and efficacy have not been

established in this age group.

Before you take

ABILIFY

When you must not take it

Do not take ABILIFY if you have

an allergy to:

aripiprazole

any of the ingredients listed at the

end of this leaflet

Symptoms of an allergic reaction

include:

rash, itching or hives on the skin

shortness of breath, wheezing or

difficulty breathing

swelling of the face, lips, tongue,

throat or other parts of the body

Do not take ABILIFY after the

expiry or use by date printed on

the pack.

If you take this medicine after this

date has passed, it may not work as

well.

Do not take ABILIFY if the

packaging is torn or shows signs of

tampering.

If this is the case, return it to your

pharmacist.

If you are not sure whether you

should start taking ABILIFY, talk

to your doctor or pharmacist.

Before you start to take it

Tell your doctor or pharmacist if

you have allergies to:

any other medicines

any other substances such as

foods, preservatives or dyes

Tell your doctor if you are

pregnant or intend to become

pregnant.

ABILIFY is not recommended for

use during pregnancy. If you need to

take ABILIFY during your

pregnancy, your doctor will discuss

with you the benefits and risks of

taking it. Babies exposed to

antipsychotics (including ABILIFY)

during the third trimester of

pregnancy are at risk of experiencing

shaking, muscle stiffness, difficulty

in feeding and/or withdrawal

symptoms. These symptoms may

ABILIFY™

resolve spontaneously or require

additional medical treatment.

Tell your doctor or pharmacist if

you are breast-feeding or plan to

breast-feed.

It is recommended that you do not

breast-feed while taking ABILIFY,

as it may pass into breast milk and

therefore there is a possibility that the

breast-fed baby may be affected.

Tell your doctor if you have, or

have had any medical conditions,

especially the following:

a reaction to some medicines with

a sudden increase in body

temperature, sweating, fast heart

beat, muscle stiffness and

fluctuating blood pressure, which

may lead to coma. This reaction

is called neuroleptic malignant

syndrome.

a reaction to some medicines with

abnormal movements of the

tongue, or other uncontrolled

movements of the mouth, tongue,

cheeks or jaw which may

progress to the arms and legs.

This reaction is called tardive

dyskinesia.

low blood pressure

problems with your heart or blood

vessels

epilepsy, seizures or fits

problems with your oesophagus

(food pipe) such as difficulty in

swallowing.

high blood sugar or diabetes

mellitus

Alzheimer's disease or dementia

alcohol or drug abuse or

dependence or a history of one of

these

venous thromboembolism or are

at risk of venous

thromboembolism

lactose intolerance

Tell your doctor if you have past

experience of excessive gambling.

Tell your doctor if you drink

alcohol.

Your doctor may advise you to avoid

alcohol as it can magnify the side-

effects of this medicine.

If you have not told your doctor or

pharmacist about any of the above,

tell them before you start taking

ABILIFY.

Taking other medicines

Tell your doctor or pharmacist if

you are taking any other

medicines, including any that you

buy without a prescription from

your pharmacy, supermarket or

health food shop.

Some medicines and ABILIFY may

interfere with each other. These

include:

medicines used to treat brain

disorders such as, anxiety,

depression, mood swings,

epilepsy or seizures, Parkinson's

disease or insomnia.

medicines used to treat high

blood pressure

medicines used to treat fungal

infections

medicines used to treat heart

rhythm disturbances

medicines used to treat bacterial

or viral infections

a medicine called cyclosporin (

Neoral

; Sandimmun

a medicine called cimetidine

(Tagamet

; Magicul

These medicines may be affected by

ABILIFY, or may affect how well it

works. Your doctor may need to

adjust your dose of Abilify or of the

other medicine.

Eating grapefruit or drinking

grapefruit juice may affect how

ABILIFY works.

Your doctor or pharmacist may have

more information on medicines to be

careful with or avoid while taking

ABILIFY.

How to take ABILIFY

Follow all directions given to you

by your doctor or pharmacist

carefully.

They may differ from the

information contained in this leaflet.

Your doctor or pharmacist will tell

you how much you will need to take

each day. This will depend on your

condition and whether you are taking

any other medicines.

The label put on the carton by the

pharmacist will tell you how much

you should take.

If you do not understand the

instructions on the carton, ask

your doctor or pharmacist for

help.

How to take it

ABILIFY tablets should be

swallowed whole and washed down

with a glass of water.

Take ABILIFY at about the same

time each day.

Unless your doctor gives you other

directions, you should take ABILIFY

only once a day.

Taking the medicine at the same time

each day will have the best effect. It

will also help you remember when to

take it.

It does not matter whether you take

ABILIFY with or without food.

If you forget to take it

If it is almost time for your next

dose, skip the dose you missed and

take your next dose when you are

meant to.

Otherwise, take it as soon as you

remember, and then go back to

taking your medicine as you would

normally.

Do not take a double dose to make

up for the dose that you missed.

This may increase the chance of you

getting an unwanted side effect.

If you are not sure what to do, ask

your doctor or pharmacist.

ABILIFY™

If you have trouble remembering

to take your medicine, ask your

pharmacist for some hints.

How long to take it

Continue taking ABILIFY for as

long as your doctor tells you.

ABILIFY helps to control your

condition but does not cure it.

Therefore you must take ABILIFY

every day. Improvement in

symptoms may take several days to

some weeks to occur. Even if you

feel better do not stop taking

ABILIFY unless your doctor tells

you to.

If you take too much

(overdose)

Immediately telephone your doctor

or pharmacist or the Poisons

Information Centre (telephone

131126), or go to the Accident

Emergency Centre at your nearest

hospital, if you or anyone else may

have taken too much ABILIFY. Do

this even if there are no signs of

discomfort or poisoning.

You may need urgent medical

attention.

While you are taking

ABILIFY

Things you must do

Tell any doctors, dentists or

pharmacists who are treating you

that you are taking ABILIFY.

If you are about to be started on

any new medicine, tell your doctor,

dentist and pharmacist that you

are taking ABILIFY.

If you plan to have any kind of

surgery that needs a general

anaesthetic, tell your doctor or

dentist that you are taking

ABILIFY.

If you become pregnant while

taking ABILIFY, tell your doctor

immediately.

Be sure to keep all of your doctor's

appointments so that your progress

can be checked.

Things you must not do

Do not give ABILIFY to anyone

else, even if their symptoms seem

similar or they have the same

condition as you.

Do not take ABILIFY to treat any

other complaints unless your

doctor or pharmacist tells you to.

Do not stop taking ABILIFY or

lower the dosage, even if you are

feeling better, without checking

with your doctor.

If you stop taking ABILIFY

suddenly your condition may worsen.

Do not take more of this medicine

and do not take it more often than

your doctor has ordered.

Things to be careful of

Make sure that you know how you

react to ABILIFY before you drive

a car, operate machinery or do

anything else that could be

dangerous if you are dizzy or light

headed or not alert.

ABILIFY may cause some people to

become drowsy or less alert than they

are normally or cause light-

headedness, dizziness or tiredness. If

this occurs do not undertake the

activity.

If ABILIFY makes you feel light-

headed, dizzy or faint, be careful

when getting up from a sitting or

lying position.

Getting up slowly may help.

Be careful when drinking alcohol

while taking ABILIFY.

Your doctor may suggest you avoid

alcohol while you are being treated

with ABILIFY.

Make sure you keep cool in hot

weather and keep warm in cool

weather.

ABILIFY may affect the way your

body reacts to temperature changes.

It may prevent sweating, even during

heatwaves. You may feel dizzy or

faint if you are too hot. To stay cool

in hot weather, try to do the

following:

wear light clothing

spend time in air-conditioned

environments (or keep windows

open and use electric fans)

drink plenty of water

take cool baths or showers and

avoid hot baths and saunas

try to restrict exercise or heavy

work to cool parts of the day

Side-Effects

Tell your doctor or pharmacist as

soon as possible if you do not feel

well while you are taking

ABILIFY.

Like other medicines ABILIFY may

cause some unwanted side effects.

These are likely to vary from patient

to patient. ABILIFY is generally

well-tolerated and the side effects are

often hard to distinguish from disease

symptoms. It is important that you

tell your doctor as soon as possible

about any unwanted effects.

Ask your doctor or pharmacist to

answer any questions you may

have.

Tell your doctor if you notice any

of the following side effects and

they worry you:

headache

indigestion

nausea

vomiting

insomnia

constipation

light-headedness

drowsiness

agitation

anxiety

inability to sit or stand still;

restless movement of the arms

and legs such as tapping,

ABILIFY™

marching in places, rocking,

crossing and uncrossing the legs.

These are the more common side

effects of ABILIFY

Tell your doctor if you notice the

following side effects:

feeling dizzy especially when

getting up from a lying or sitting

position

altered or increased sexual

interest

These side effects are uncommon.

high blood sugar (excessive thirst,

hunger and weakness) or the

onset or worsening of diabetes

This side effect is rare.

weight gain

weight loss

loss of appetite

excessive sweating

drowsiness

high blood pressure

chest pain

frequent infections such as fever,

severe chills, sore throat or mouth

ulcers

bleeding or bruising more easily

than normal

speech disorder

urinary incontinence

difficulty swallowing

hiccups

These side effects are very rare.

Tell your doctor if you have

obsessive (recurring) thoughts or

behaviours or trouble controlling

impulsive urges or while taking

ABILIFY.

Obsessive compulsive behaviours

(feeling the need to check things

repeatedly or having certain thoughts

repeatedly), gambling urges, sexual

urges, compulsive spending, binge or

compulsive eating and other urges

have occurred in some patients.

Tell your doctor immediately or go

to Accident and Emergency at

your nearest hospital if you notice

any of the following:

seizure, fits or convulsions.

fainting.

abnormal movements of the

tongue, or other uncontrolled

movements of the tongue, mouth,

cheeks, or jaw which may

progress to the arms and legs.

sudden increase in body

temperature, sweating, fast heart

beat, muscle stiffness, high blood

pressure and convulsions.

rash.

allergic reaction (rash, itching or

hives on the skin; shortness of

breath, wheezing or difficulty

breathing; swelling of the face,

lips, tongue, throat or other parts

of the body).

muscle pain, muscle weakness or

muscle stiffness.

inflammation of the pancreas,

severe upper stomach pain often

with nausea and vomiting.

disorder of body temperature

regulation resulting in low body

temperature or high body

temperature.

painful irreversible erection.

difficulty in passing urine.

yellowing of the skin and/or eyes,

also called jaundice with or

without nausea, vomiting, loss of

appetite, feeling generally unwell,

fever, itching and dark coloured

urine.

serious lung infection with fever,

chills, shortness of breath, cough,

chest pain and blood streaked

phlegm.

thoughts or talk about death or

suicide; thoughts or talk about

self-harm or doing harm to

others; any recent attempts at

self-harm; an increase in

aggressive behaviour, irritability

or agitation. If you or someone

you know is showing these signs

contact your doctor or a mental

health advisor right away or go to

the nearest hospital for treatment.

These are very serious side effects.

You may need urgent medical

attention or hospitalisation.

All of these side effects are very rare.

Other side effects not listed above

may occur in some patients.

Also, while taking ABILIFY, some

elderly patients with dementia have

suffered serious side effects such as a

"mini" stroke, stroke, pneumonia or

heart problems. These serious side

effects can be life threatening.

Tell your doctor or pharmacist if

you notice anything that is making

you feel unwell.

Do not be alarmed by this list of

possible side effects.

You may not experience any or only

some of them.

After using ABILIFY

Storage

Store ABILIFY in a cool place

where the temperature stays below

30°C.

Do not store it or any other

medicine in the bathroom. Do not

leave it in the car or on window

sills.

Heat and dampness can destroy some

medicines.

Keep it where young children

cannot reach it.

A locked cupboard at least one-and-

a-half metres above the ground is a

good place to store medicines. Do

not keep outdated medicine or

medicine no longer needed.

Disposal

If your doctor tells you to stop

taking ABILIFY or the medicine

has passed its expiry date, ask your

pharmacist what to do with any

leftover medicine.

Be sure that any discarded

medicine is out of the reach of

children.

ABILIFY™

Product Description

What it looks like

5mg ABILIFY tablets are blue,

rectangular with a bevel edge and are

marked on one side with "A-007"

and "5" (Not available in New

Zealand)

10mg ABILIFY tablets are pink,

rectangular with a bevel edge and are

marked on one side with "A-008"

and "10".

15mg ABILIFY tablets are yellow,

round with a bevel edge and are

marked on one side with "A-009"

and "15".

20mg ABILIFY tablets are white to

pale yellowish white, round with a

bevel edge and are marked on one

side with "A-010" and "20".

30mg ABILIFY tablets are pink,

round with a bevel edge and are

marked on one side with "A-011"

and "30".

ABILIFY tablets are packed in

aluminium blisters in a carton. Each

carton contains 30 tablets.

Ingredients

Active ingredients:

aripiprazole

Other ingredients:

lactose, starch - maize, cellulose -

microcrystalline,

hydroxypropylcellulose and

magnesium stearate. The following

colorants are also present in the

tablets:

5mg tablets - indigo carmine

CI73015 aluminium lake (not

available in New Zealand)

10mg tablets - iron oxide red

CI77491

15mg tablets - iron oxide yellow

CI77492

20mg tablets - no colourants

30mg tablets - iron oxide red

CI77491

ABILIFY does not contain sucrose,

gluten, tartrazine or any other azo

dyes.

Sponsored by

In Australia:

Otsuka Australia Pharmaceutical Pty

Level 20, Tower A, The Zenith

821 Pacific Highway

Chatswood NSW 2067

Tel: Toll Free 1800 059 606

In New Zealand:

Pharmacy Retailing (NZ) Ltd trading

as Healthcare Logistics

58 Richard Pearse Drive

Airport Oaks

Mangere

Auckland 2022

Tel: Toll free 0800 602 200

Registration Numbers -

Australia

AUST R 90925 - 5mg tablets

AUST R 90997 - 10mg tablets

AUST R 90998 - 15mg tablets

AUST R 90999 - 20mg tablets

AUST R 91000 - 30mg tablets

Date of Preparation September 2016

ABILIFY is a trademark of Otsuka

Pharmaceutical Co., Ltd.

18-12-2018

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. Recalls Red and Green Leaf Lettuce and Cauliflower Because of Possible Health Risk

Adam Bros. Farming, Inc. of Santa Maria, California is recalling red leaf lettuce, green leaf lettuce and cauliflower harvested on November 27 through 30, 2018 out of an abundance of caution, because it may be contaminated with Escherichia coli O157:H7 bacteria (E. Coli O157:H7).

FDA - U.S. Food and Drug Administration

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

11-12-2018


The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Athens, Greece, from 28/01/2019 to 30/01/2019

The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Athens, Greece, from 28/01/2019 to 30/01/2019

The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Athens, Greece, from 28/01/2019 to 30/01/2019

Europe - EMA - European Medicines Agency

6-12-2018

Danone North America Issues Allergy Alert and Recall for Light & Fit Greek Crunch S’mores Flavor

Danone North America Issues Allergy Alert and Recall for Light & Fit Greek Crunch S’mores Flavor

Danone North America is voluntarily recalling 3,521 cases of Light & Fit® Greek Crunch Nonfat Yogurt & Toppings S’Mores Flavor sold in the United States with an expiration date of December 30, 2018 and UPC of 36632 03825. It was discovered that some of the toppers sold on the product contain peanuts and are improperly labeled. People who have an allergy to peanuts run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

5-12-2018

Enforcement Report for the Week of December 05, 2018

Enforcement Report for the Week of December 05, 2018

Recently Updated Records for the Week of December 05, 2018 Last Modified Date: Friday, November 30, 2018

FDA - U.S. Food and Drug Administration

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

1-12-2018

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 30 Nov 2018 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of the recycling process RecyPET Hungária (EU register number RECYC0146). The input is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes originating from collected post‐consumer PET containers, containing no more than 5% of PET from non‐food applications. The flakes are dried and extruded. The output of the extrusion step is cut into pellets in an underwater...

Europe - EFSA - European Food Safety Authority Publications

27-11-2018

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 3: European database of processing factors for pesticides in food

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 3: European database of processing factors for pesticides in food

Published on: Mon, 26 Nov 2018 EFSA is conducting pan‐European dietary exposure and risk assessments related to actual levels of pesticide residues in food commodities. These assessments use the pesticide occurrence data generated under the official monitoring programs of Member States, the consumption data from EFSA's comprehensive food consumption database and pesticide‐specific information such as processing factors. Currently no harmonised list of processing factors is available within Europe and wo...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Published on: Tue, 20 Nov 2018 The European Commission asked EFSA for a scientific opinion on the risks for animal and human health related to the presence of dioxins (PCDD/Fs) and DL‐PCBs in feed and food. The data from experimental animal and epidemiological studies were reviewed and it was decided to base the human risk assessment on effects observed in humans and to use animal data as supportive evidence. The critical effect was on semen quality, following pre‐ and postnatal exposure. The critical s...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year

New findings from the National Youth Tobacco Survey show that more than 3.6 million middle and high school students were current (past 30 day) e-cigarette users in 2018.

FDA - U.S. Food and Drug Administration

7-11-2018

Reactie op berichtgeving over nota Waarborgfonds

Reactie op berichtgeving over nota Waarborgfonds

Op dinsdag 30 oktober heeft minister Bruno Bruins een feitenrelaas rondom het faillissement van de MC Groep naar de Tweede Kamer gestuurd.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

31-10-2018

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft guidance on the scientific requirements for health claims related to muscle function and physical performance, prepared by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), supported by the Working Group on Claims. The draft guidance was endorsed by the Panel for public consultation ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Peer review of the pesticide risk assessment of the active substance dimethoate

Peer review of the pesticide risk assessment of the active substance dimethoate

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Italy and co‐rapporteur Member State Bulgaria for the pesticide active substance dimethoate are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of dimetho...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Guidance on the scientific requirements for health claims related to muscle function and physical performance

Guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 EFSA has asked the Panel on Nutrition, Novel Foods and Food Allergens (NDA) to update the guidance on the scientific requirements for health claims related to physical performance published in 2012. The update takes into account the experience gained by the NDA Panel with the evaluation of additional health claim applications, changes introduced to the general scientific guidance for stakeholders for health claims applications and information collected from ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Peer review of the pesticide risk assessment of the active substance methiocarb

Peer review of the pesticide risk assessment of the active substance methiocarb

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State the United Kingdom and co‐rapporteur Member State Germany for the pesticide active substance methiocarb are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative use...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of a strain of Lactobacillus hilgardii and of Lactobacillus buchneri when used as a technological additive intended to improve ensiling at a proposed application rate of 3.0 x 108 colony forming units (CFU)/kg fresh material. The two bacterial species are considered by EFS...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. EAST TRADING CORP. of Bronx, NY is recalling Fruits Du Sud Golden Seedless Raisins (Lot No. FDS T499/18) 30 lbs Box, because they contain undeclared SULFITES. People who have a severe sensitivity to sulfites run the risk of serious or life-threatening reactions if they consume these products.

FDA - U.S. Food and Drug Administration

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

25-9-2018

Voluntary Recall on Harris Teeter Low Fat Cookies & Cream Frozen Yogurt Due to Undeclared Peanut Product

Voluntary Recall on Harris Teeter Low Fat Cookies & Cream Frozen Yogurt Due to Undeclared Peanut Product

Harris Teeter is notifying shoppers of a voluntarily recall of Harris Teeter Low Fat Frozen Yogurt Cookies & Cream 1.5 qt laminated cartons, UPC 0 72036 98182 0, with all SELL BY DATES up to 07/30/19 due to undeclared peanut product.

FDA - U.S. Food and Drug Administration

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

31-8-2018

Peer review of the pesticide risk assessment of the active substance cypermethrin

Peer review of the pesticide risk assessment of the active substance cypermethrin

Published on: Thu, 30 Aug 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Belgium and co‐rapporteur Member State Germany for the pesticide active substance cypermethrin are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of cype...

Europe - EFSA - European Food Safety Authority Publications

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

6-8-2018

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC Recalls Pat's Cat Turkey, and Ground Lamb Pet Food, because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling 30 1-lb containers of Pat's Cat Turkey Cat Food and 40 2-lb containers of Ground Lamb Dog Food because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes can cause serious and sometimes fatal infections in animals eating the products.

FDA - U.S. Food and Drug Administration

31-7-2018

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

July 30, 2018: Two People Guilty of Distributing Tramadol Pills

FDA - U.S. Food and Drug Administration

19-12-2018

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar:  https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDA pic.twitter.com/sHElqFFODy

FDA - U.S. Food and Drug Administration

18-12-2018


Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Orphan designation: Mercaptopurine (oral suspension), Treatment of acute lymphoblastic leukaemia, 30/04/2009, Positive

Europe - EMA - European Medicines Agency

18-12-2018


Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Europe - EMA - European Medicines Agency

30-11-2018

Pregabalin Zentiva k.s (Zentiva, k.s.)

Pregabalin Zentiva k.s (Zentiva, k.s.)

Pregabalin Zentiva k.s (Active substance: pregabalin) - Centralised - Yearly update - Commission Decision (2018)8149 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Pioglitazone Teva (Teva B.V.)

Pioglitazone Teva (Teva B.V.)

Pioglitazone Teva (Active substance: pioglitazone) - Centralised - Yearly update - Commission Decision (2018)8159 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Keppra (UCB Pharma S.A.)

Keppra (UCB Pharma S.A.)

Keppra (Active substance: levetiracetam) - Centralised - Yearly update - Commission Decision (2018)8160 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

30-11-2018

Pioglitazone Teva Pharma (Teva B.V.)

Pioglitazone Teva Pharma (Teva B.V.)

Pioglitazone Teva Pharma (Active substance: pioglitazone) - Centralised - Yearly update - Commission Decision (2018)8158 of Fri, 30 Nov 2018

Europe -DG Health and Food Safety

15-11-2018

Flixabi (Samsung Bioepis NL B.V.)

Flixabi (Samsung Bioepis NL B.V.)

Flixabi (Active substance: infliximab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7549 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4020/T/30

Europe -DG Health and Food Safety

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Freeline Therapeutics Ltd)

EU/3/18/2080 (Active substance: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant) - Orphan designation - Commission Decision (2018)7281 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/127/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Spark Therapeutics Ireland Ltd)

EU/3/18/2079 (Active substance: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII) - Orphan designation - Commission Decision (2018)7280 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/104/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2078 (Sellas Life Sciences Limited)

EU/3/18/2078 (Sellas Life Sciences Limited)

EU/3/18/2078 (Active substance: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG) - Orphan designation - Commission Decision (2018)7279 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/091/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2077 (Worphmed Srl)

EU/3/18/2077 (Worphmed Srl)

EU/3/18/2077 (Active substance: Melatonin) - Orphan designation - Commission Decision (2018)7278 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/077/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2075 (Consorcio Centro de InvestigaciOn BiomEdica en Red M.P.)

EU/3/18/2075 (Consorcio Centro de InvestigaciOn BiomEdica en Red M.P.)

EU/3/18/2075 (Active substance: Gefitinib) - Orphan designation - Commission Decision (2018)7276 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/090/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2074 (PhaRA bvba)

EU/3/18/2074 (PhaRA bvba)

EU/3/18/2074 (Active substance: Avapritinib) - Orphan designation - Commission Decision (2018)7275 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/079/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Fondazione Telethon)

EU/3/18/2073 (Active substance: Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA) - Orphan designation - Commission Decision (2018)7274 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/113/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Loxo Oncology Limited)

EU/3/18/2071 (Active substance: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile) - Orphan designation - Commission Decision (2018)7272 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (FGK Representative Service GmbH)

EU/3/18/2072 (Active substance: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate) - Orphan designation - Commission Decision (2018)7273 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/102/18

Europe -DG Health and Food Safety

18-10-2018

ABILIFY MAINTENA (Otsuka Pharmaceutical Netherlands B.V.)

ABILIFY MAINTENA (Otsuka Pharmaceutical Netherlands B.V.)

ABILIFY MAINTENA (Active substance: Aripiprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6925 of Thu, 18 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/002755/T/0026

Europe -DG Health and Food Safety

30-9-2018

Roteas (Daiichi Sankyo Europe GmbH)

Roteas (Daiichi Sankyo Europe GmbH)

Roteas (Active substance: edoxaban) - PSUSA - Modification - Commission Decision (2018)5089 of Sun, 30 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10387/201710

Europe -DG Health and Food Safety

17-9-2018

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction.   Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept.

FDA - U.S. Food and Drug Administration

30-8-2018

Steglatro (Merck Sharp and Dohme B.V.)

Steglatro (Merck Sharp and Dohme B.V.)

Steglatro (Active substance: ertugliflozin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5789 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4315/T/2

Europe -DG Health and Food Safety

30-8-2018

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (Active substance: influenza vaccine (live attenuated, nasal)) - Centralised - Variation - Commission Decision (2018)5815 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2617/II/82

Europe -DG Health and Food Safety

29-8-2018

ABILIFY MAINTENA (Otsuka Pharmaceutical Europe Ltd)

ABILIFY MAINTENA (Otsuka Pharmaceutical Europe Ltd)

ABILIFY MAINTENA (Active substance: Aripiprazole) - Centralised - Renewal - Commission Decision (2018)5780 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2755/R/25

Europe -DG Health and Food Safety

28-8-2018

Abilify (Otsuka Pharmaceutical Netherlands B.V.)

Abilify (Otsuka Pharmaceutical Netherlands B.V.)

Abilify (Active substance: aripiprazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5681 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/471/T/131

Europe -DG Health and Food Safety

3-8-2018

Scandonest and associated names

Scandonest and associated names

Scandonest and associated names (Active substance: mepivacaine) - Community Referrals - Art 30 - Commission Decision (2018)5380 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-30/1455

Europe -DG Health and Food Safety

1-8-2018

Bridion (Merck Sharp and Dohme B.V.)

Bridion (Merck Sharp and Dohme B.V.)

Bridion (Active substance: sugammadex) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5213 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/885/T/30

Europe -DG Health and Food Safety

30-7-2018

Nityr (Cycle Pharmaceuticals Ltd)

Nityr (Cycle Pharmaceuticals Ltd)

Nityr (Active substance: nitisinone) - Centralised - Authorisation - Commission Decision (2018)5446 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4582

Europe -DG Health and Food Safety

30-7-2018

Esmya (Gedeon Richter Plc.)

Esmya (Gedeon Richter Plc.)

Esmya (Active substance: ulipristal) - Referral - Commission Decision (2018)5101 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2041/A-20

Europe -DG Health and Food Safety